Longeveron Secures Chinese Patent for Methods Assessing Potency of Mesenchymal Stem Cells

Longeveron has been granted a patent in China for its potency assay methods designed to assess human mesenchymal stem cells (MSCs). The announcement, made on April 8, 2026, highlights the company’s achievement in securing intellectual property protection for its proprietary technology in one of the world’s largest markets. This development marks an important step for Longeveron in advancing its research and applications related to regenerative medicine.

The patented methods focus on evaluating the potency of MSCs, which are stem cells derived from bone marrow or other tissues that have potential therapeutic uses. These assays aim to measure specific biological properties of MSCs, ensuring their effectiveness and consistency for clinical applications. By obtaining this patent in China, Longeveron strengthens its position in the global stem cell research field and expands its ability to protect and utilize its innovations internationally.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI